Abstract. Objective: to analyze the dynamics of antibiotic resistance of Acinetobacter spp. isolated from patients in ICU. To identify effective antibiotics against isolated strains.
Material and methods. We analyzed the isolated strains and analyzed the results of determining the sensitivity of Acinetobacter spp. to antibacterial drugs. The pathogens were isolated from ICU patients in 2008-2019. Clinical material for microbiologic examination included wound secretions, bronchoalveolar lavage, abdominal cavity exudate, abscess contents, bile, urine, and blood. Microbiological studies were carried out in the laboratories of microbiological of the State Institution “RSSPMC for surgery named after V.Vakhidov"
Results. Due to the introduction of recommended protocols for antibacterial prophylaxis and treatment, methods of monitoring the effectiveness of antimicrobial therapy, the introduction of forecasting methods (identification of risk groups and more targeted antibiotic prophylaxis of nosocomial infections), effective criteria for ventilator modes, approaches to pathogenetic therapy, nutritional support, etc. since 2012, there is a decrease in the frequency of purulent-septic complications, so that in 2012-2019 in the cardiac block, it was from 1.5-1.3 to 0.3-0.1%, in the abdominal block - from 1.0-1.9 to 0.5-0.2%, in the thoracic block - from 0.7-0.5 to 0.03-0.02%.
Conclusion. The increasing antibiotic resistance of Acinetobacter spp. causes the necessity to study antibiotic grams of all strains isolated from patients for adequate choice of means of effective antibiotic therapy. The obtained data were used to optimize empirical antibiotic therapy in patients with purulent-septic complications in ICU.
References:
1. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014; 71 (3): 292301. doi: 10.1111/2049-632X.12125.
2. Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. Reservoirs of Non-baumannii Acinetobacter Species. Front Microbiol. 2016; 7: 49. doi: 10.3389/fmicb.2016.00049.
3. Ershova K, Savin I, Kurdyumova N, Wong D, Danilov G, Shifrin M, et al. Implementing an infection control and prevention program decreases the incidence of healthcareassociated infections and antibiotic resistance in a Russian neuro-ICU. Antimicrob Resist Infect Control. 2018; 7: 94. doi: 10.1186/s13756-018-0383-4.
4. Briko NI, Brusina EB, Zueva LP, Kovalishena OV, Ryapis L, StasenkoVL, et al. Hospital Strain – Mysterious Reality. Epidemiology and Vaccinal Prevention. 2013; № 1 (68): 30-35. Russian (Брико Н.И., Брусина Е.Б., Зуева Л.П., Ковалишена О.В., Ряпис Л.А., Стасенко В.Л. и др. Госпитальный штамм – непознанная реальность // Эпидемиология и вакцинопрофилактика. 2013. № 1 (68). С. 30-35).
5. Brusina EB, Barbarash OL. Risk management of infections connected with providing medical aid (risk management). Medical Almanac. 2015; 5 (40): 22-25. Russian (Брусина Е.Б., Барбараш О.Л. Управление риском инфекций, связанных с оказанием медицинской помощи (риск-менеджмент) // Медицинский альманах. 2015. № 5 (40). С. 22-25).
6. Cray JA, Bell AN, Bhaganna P, Mswaka AY, Timson DJ, Hallsworth JE. The biology of habitat dominance; can microbes behave as weeds? Microb Biotechnol. 2013; 6 (5): 453-492. doi: 10.1111/1751-7915.12027.
7. Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2011; 26 (2): 101-112. doi: 10.1264/jsme2.ME10179.
8. Ershova K, Savin I, Kurdyumova N, Wong D, Danilov G, Shifrin M, et al. Implementing an infection control and prevention program decreases the incidence of healthcareassociated infections and antibiotic resistance in a Russian neuro-ICU. Antimicrob Resist Infect Control. 2018; 7: 94. doi: 10.1186/s13756-018-0383-4.
9. Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist. 2018; 11: 22772299. doi: 10.2147/IDR.S169894.
10. Kenyon JJ, Hall RM. Variation in the complex carbohydrate biosynthesis loci of Acinetobacter baumannii genomes. PLoS One. 2013; 8 (4): e62160. doi: 10.1371/journal.pone.0062160.
11. Salzer HJ, Rolling T, Schmiedel S, Klupp EM, Lange C, Seifert H. Severe community-acquired bloodstream infection with Acinetobacter ursingii in person who injects drugs. Emerg Infect Dis. 2016; 22 (1): 134-137. doi: 10.3201/eid2201.151298.
12. Towner A, Park AN, Gander R, Orr K, Arocha D, Zhang S, et al. Acinetobacter infections and outcomes at an academic medical center: a disease of long term care. Open Forum Infectious Diseases. 2015; 2 (1): ofv023. doi: 10.1093/ofid/ofv023.
13. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev. 2017; 30 (1): 409-447. doi: 10.1128/ CMR.00058-16.
14. WHO priority pathogens list for R&D of new antibiotics. Acinetobacter: Microbiological, Pathogenetic and Resistant Properties [Electronic resource]. Available at: https: //www. who.int/ru/news-room/detail/27-02-2017-who-publishes-listof-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed 15.02.2019).
SCIENCE & INNOVATION